201TiP Density lowering effect of ovarian function suppression in premenopausal breast cancer patients who had no density change with one year of tamoxifen treatment (DELFINO study)

Abstract

Mammographic density has been known to be a risk factor for breast cancer. Moreover, tamoxifen reduces mammographic density, and the change in mammographic density is a predictive surrogate marker for response to adjuvant tamoxifen therapy. If there is no change or rather an increase in mammographic density, the effect of tamoxifen therapy is considered to be less, and intervention for additional treatment such as ovarian function suppression (OFS) may be considered in the group with a low response to the treatment.